# Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment

> **NCT07638722** · PHASE2 · NOT_YET_RECRUITING · sponsor: **SWOG Cancer Research Network** · enrollment: 138 (estimated)

## Conditions studied

- Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Recurrent Nodal Marginal Zone Lymphoma
- Recurrent Splenic Marginal Zone Lymphoma
- Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Refractory Nodal Marginal Zone Lymphoma
- Refractory Splenic Marginal Zone Lymphoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Biopsy
- **PROCEDURE:** Computed Tomography
- **BIOLOGICAL:** Mosunetuzumab
- **DRUG:** Polatuzumab Vedotin
- **PROCEDURE:** Positron Emission Tomography
- **OTHER:** Survey Administration
- **DRUG:** Zanubrutinib

## Key facts

- **NCT ID:** NCT07638722
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-03
- **Primary completion:** 2034-04-03
- **Final completion:** 2035-04-03
- **Target enrollment:** 138 (ESTIMATED)
- **Last updated:** 2026-07-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07638722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07638722, "Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07638722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*